Ftse Mib
34.243,32
-0,39%
DAX
18.480,94
-0,64%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,00%
Bitcoin
63.811,57
-1,60%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX BioPharmX Corporation (BPMX) BioPharmX Corporation (BPMX) Notizie

BPMX

BioPharmX (BPMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX
DataOraFonteTitoloSimboloCompagnia
29/06/201614:00PR Newswire (US)BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing BacteriaAMEX:BPMXBioPharmX Corporation
28/06/201621:05Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:BPMXBioPharmX Corporation
15/06/201600:50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:BPMXBioPharmX Corporation
14/06/201622:57Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)AMEX:BPMXBioPharmX Corporation
14/06/201622:49Edgar (US Regulatory)Quarterly Report (10-q)AMEX:BPMXBioPharmX Corporation
14/06/201622:08Edgar (US Regulatory)Current Report Filing (8-k)AMEX:BPMXBioPharmX Corporation
14/06/201622:05PR Newswire (US)BioPharmX Corporation Reports First Quarter Financial ResultsAMEX:BPMXBioPharmX Corporation
07/06/201614:00PR Newswire (US)BioPharmX to Report First Quarter Financial Results on June 14, 2016AMEX:BPMXBioPharmX Corporation
01/06/201622:12Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)AMEX:BPMXBioPharmX Corporation
31/05/201622:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:BPMXBioPharmX Corporation
16/05/201614:00PR Newswire (US)BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effectiv...AMEX:BPMXBioPharmX Corporation
12/05/201622:15PR Newswire (US)BioPharmX CEO Steps Down, Board Appoints Independent Director to Serve as ChairmanAMEX:BPMXBioPharmX Corporation
09/05/201613:00PR Newswire (US)BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breast...AMEX:BPMXBioPharmX Corporation
02/05/201622:11Edgar (US Regulatory)Annual Report (10-k)AMEX:BPMXBioPharmX Corporation
26/04/201622:10PR Newswire (US)BioPharmX Corporation Reports Fourth Quarter and Fiscal Year End Financial ResultsAMEX:BPMXBioPharmX Corporation
25/04/201614:00PR Newswire (US)BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for AcneAMEX:BPMXBioPharmX Corporation
13/04/201614:00PR Newswire (US)BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016AMEX:BPMXBioPharmX Corporation
04/04/201614:30PR Newswire (US)Health Canada Approves BioPharmX Corporation Study of Violet® IodineAMEX:BPMXBioPharmX Corporation
01/04/201617:45PR Newswire (US)BioPharmX Corporation Announces Closing Of $4.3 Million Public OfferingAMEX:BPMXBioPharmX Corporation
30/03/201622:11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:BPMXBioPharmX Corporation
29/03/201615:16PR Newswire (US)BioPharmX Corporation Announces Pricing Of Public Offering To Raise $4.3 MillionAMEX:BPMXBioPharmX Corporation
28/03/201622:05PR Newswire (US)BioPharmX Corporation Announces Proposed Public Offering of Common Stock and WarrantsAMEX:BPMXBioPharmX Corporation
22/03/201613:00PR Newswire (US)BioPharmX Corporation Initiates Post-Market Phase IV Study for Fibrocystic Breast Condition (FBC) and Cyclic MastalgiaAMEX:BPMXBioPharmX Corporation
03/03/201615:00PR Newswire (US)BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01AMEX:BPMXBioPharmX Corporation
25/02/201618:30PR Newswire (US)BioPharmX Announces Therapeutic Dermatology Advisory BoardAMEX:BPMXBioPharmX Corporation
16/02/201615:43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:BPMXBioPharmX Corporation
05/02/201612:02Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:BPMXBioPharmX Corporation
01/02/201615:00PR Newswire (US)BioPharmX Appoints Marie-Louise Bots as Senior VP of Corporate DevelopmentAMEX:BPMXBioPharmX Corporation
27/01/201620:52Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:BPMXBioPharmX Corporation
27/01/201615:00PR Newswire (US)BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of DirectorsAMEX:BPMXBioPharmX Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX

La tua Cronologia

NASDAQ
GBRG
Goldenbridge Acquisition
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network